Precursor B Lymphoblastic Leukemia With Surface Light Chain Immunoglobulin Restriction A Report of 15 Patients

Size: px
Start display at page:

Download "Precursor B Lymphoblastic Leukemia With Surface Light Chain Immunoglobulin Restriction A Report of 15 Patients"

Transcription

1 Hematopathology / PRECURSOR B LYMPHOBLASTIC LEUKEMIA Precursor B Lymphoblastic Leukemia With Surface Light Chain Immunoglobulin Restriction A Report of 15 Patients Rina Kansal, MD, 1 George Deeb, MD, 1 Maurice Barcos, MD, PhD, 2 Meir Wetzler, MD, 3 Martin L. Brecher, MD, 4 AnneMarie W. Block, PhD, 5 and Carleton C. Stewart, PhD 6 Key Words: Precursor B cell; Acute lymphoblastic leukemia; Surface immunoglobulin positive acute leukemia; Flow cytometry; WHO classification; Immunophenotyping Abstract We describe 15 patients (9 children) with precursor B-cell (pb) acute lymphoblastic leukemia (ALL) with surface immunoglobulin (sig) light chain restriction revealed by flow cytometric immunophenotyping (FCI). The same sig+ immunophenotype was present at diagnosis and in 3 relapses in 1 patient. In 15 patients, blasts were CD19+CD10+ (bright coexpression) in 14, CD34+ in 12, surface κ+ in 12, surface λ+ in 3; in 8 of 8, terminal deoxyribonucleotidyl transferase (TdT)+; and in 4, surface IgD+ in 2 and surface IgM+ in 1. The 3 CD34 cases included 1 TdT+ case, 1 with t(1;19)(q23;p13), and 1 infant with 70% marrow blasts. One adult had CD10 CD19+CD20 CD22+CD34+ TdT+sIg+ blasts with t(2;11)(p21;q23). Blasts were L1 or L2 in all cases (French-American-British classification). Karyotypic analysis in 12 of 12 analyzable cases was negative for 8q24 (myc) translocation. Karyotypic abnormalities, confirmed by fluorescence in situ hybridization in 6 cases, included hyperdiploidy, t(1;19)(q23;p13), t(12;21)(p13;q22), t(9;22)(q34;q11), t(2;11)(p21;q23), and trisomy 12. The sig light chain restriction in pb ALL might be present in neoplasms arising from the early, intermediate, and late stages of precursor B-cell maturation; sig light chain restriction revealed by FCI does not necessarily indicate a mature B-cell phenotype, further emphasizing the importance of a multidisciplinary approach to diagnosing B-lymphoid neoplasms. Neoplasms of the B-lymphoid cell may have a precursor B-cell phenotype or a mature B-cell phenotype, as described in the World Health Organization (WHO) classification of hematopoietic malignant neoplasms. 1 The latter category includes Burkitt leukemia/lymphoma and other neoplasms of the mature B-cell, which may have a leukemic manifestation. In the diagnostic evaluation of these B-cell neoplasms, flow cytometric immunophenotypic (FCI) analysis has a critical role in the differentiation of a precursor B-cell phenotype from a mature B-cell phenotype. 2 While a mature B-cell phenotype shows the presence of surface immunoglobulins by FCI analysis, this expression typically is absent in a precursor B-cell phenotype. Precursor B-cell (pb) acute lymphoblastic leukemia (ALL) is a neoplasm of B lymphoblasts that characteristically are negative for surface light chain immunoglobulins by FCI analysis and express markers related to the degree of B-cell differentiation. 1-3 Cases of pb ALL with the expression of immunoglobulins include those described as transitional pre-b ALL, which express cytoplasmic and surface IgM but no surface light chain immunoglobulins. 4 The expression of surface light chain immunoglobulins in pb ALL seems to be rare in the pediatric age group. 5 In adults, we found 7 published cases of ALL with surface light chain immunoglobulin restriction 6,7 that would be classified as pb ALL by the WHO classification. Previous authors have suggested that the lymphoblasts in these pb ALL cases might represent a B-cell stage intermediate between the transitional pre B-cell stage and the mature B cell. 6,7 We present findings from 15 patients with pb ALL with surface light chain immunoglobulin restriction, diagnosed by a multidisciplinary approach in a single institution, which demonstrate 512 Am J Clin Pathol 2004;121: Downloaded 512 from

2 Hematopathology / ORIGINAL ARTICLE for the first time that surface light chain immunoglobulin restriction in precursor B lymphoblasts is not confined to any particular stage of B-lymphoblast differentiation and, instead, may be seen in a heterogeneous group of pb ALLs showing different degrees of differentiation of pb lymphoblasts. To the best of our knowledge, this is the largest reported group of cases with this unusual immunophenotypic expression in pb ALL. Materials and Methods This single-institution retrospective study was designed at Roswell Park Cancer Institute (RPCI; Buffalo, NY) following an index case of pb ALL with surface light chain immunoglobulin restriction, which was observed in the clinical practice of one of us (R.K.) at Buffalo General Hospital, Buffalo, NY. The flow cytometry database at RPCI was searched for the period January 1995 to December 2001 for all cases of acute lymphoblastic leukemia and for all Blineage malignancies with surface immunoglobulin (sig) expression. The pathology database also was searched to identify cases of pb ALL. At least 198 cases of ALL were identified; however, the cases retrieved by the specific key word searches represented only a subset of the total number of cases of ALL analyzed by flow cytometry at RPCI, precluding an estimate of the incidence of sig+ pb ALL in our cases. The immunophenotypic and relevant pathologic data were reviewed, and 19 cases of pb ALL were identified in 15 patients, showing sig light chain restricted neoplastic cells by FCI analysis. All cases were classified according to the WHO criteria. 1 Cases of Burkitt lymphoma/leukemia were excluded. The clinical, morphologic, cytogenetic, and flow cytometric immunophenotypic findings were reviewed in all 19 cases. Clinical information, including age, sex, sites of involvement by disease, leukocyte counts at diagnosis, and treatment and clinical follow-up data were recorded by review of medical records. Flow Cytometry Multiparameter flow cytometry was performed in all cases in the Laboratory of Flow Cytometry, RPCI, as previously described. 8,9 All cases were analyzed by 4-color (15 cases) or 3-color flow cytometry ( ; 4 cases in 3 patients) using a FACScan Flow Cytometer (Becton Dickinson, San Jose, CA). An acute leukemia panel of antibodies was used in all cases. At RPCI, this panel routinely includes surface κ and λ, HLA-DR, CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD11c, CD13, CD14, CD15, CD16, CD19, CD20, CD22, CD23, CD25, CD32, CD33, CD34, CD38, CD41, CD45, CD56, CD57, CD64, CD71, and CD79b. Surface IgD and IgM were analyzed in 4 cases using 3-color FCI analysis. The 4-color fluorochrome combinations included fluorescein isothiocyanate (FITC)/phycoerythrin (PE)/peridinium chlorophyll protein complex (PerCP) or PE-cyanin-5 (PECY5 or Tricolor (TC, Caltag, Burlingame, CA)/allophycocyanin (APC). The 3-color fluorochrome combinations included FITC/PE/PerCP or PECY5 or TC. The corresponding antibody combinations included CD3/CD14/PerCP-HLA-DR/CD45, CD3/CD4/TC-CD8/CD45, CD7/CD13/TC-CD2/CD19, CD5/λ/PECY5-CD19/κ, CD20/CD11c/TC-CD22/CD25, CD5/CD19/PECY5-CD10/CD34, CD11b/CD13/PECY5- CD33/CD34, CD15/CD56/PECY5-CD19/CD34, and IgD/IgM/PECY5-CD19. The surface κ and λ antibodies used were APC-κ (clone TB28-2, BD Biosciences, San Jose, CA) and PE-λ (clone , BD Biosciences). All other antibodies were obtained from the following sources: Caltag (CD2, CD8, CD14, CD15, CD16, CD19, CD22, CD23, CD32, CD41, CD57, CD71, CD79b, IgD, and IgM), BD Biosciences (CD3, CD4, CD5, CD11c, CD13, CD14, CD20, CD25, CD34, CD45, CD64, and HLA-DR), and Immunotech-Coulter, Hialeah, FL (CD7, CD10, CD11b, CD19, CD33, CD38, CD56, and CD71). The samples analyzed included 18 bone marrow aspirates and 1 peripheral blood sample. Cell viability was determined by using ethidium monoazide fluorescence, as previously described. 10 All specimens exhibited more than 98% viable cells after processing. All data were obtained in list mode and displayed as 2-parameter dot plots using WinList multiparameter analysis software (Verity Software House, Topsham, ME). The antibody panel that best resolved leukemia cells was chosen to identify the cell population of interest, and the data were reanalyzed ( back gated ) to produce bivariate displays in the forward vs the side scatter plot. New regions were drawn around the cells of interest in this display ( leukemia gate ), and these scatter regions then were used to analyze all other panels. Cells stained with isotype-matched antibody-fluorochrome combinations and biologically negative control cells within each tube were used as negative controls. The cell clusters of interest were called positive for a surface antigen if they showed a distinct shift in fluorescence intensity in comparison with the negative controls. The intensity of fluorescence was reported as dim if the mean fluorescence intensity was within the second logarithmic decade (the first logarithmic decade being negative). Morphologic Examination and Terminal Deoxyribonucleotidyl Transferase Immunohistochemical Analysis The corresponding peripheral blood smears, bone marrow aspirate smears (Wright-Giemsa stained and cytochemically stained), and H&E-stained bone marrow aspirate clot sections and core biopsy sections were reviewed. The Downloaded from Am J Clin Pathol 2004;121:

3 Kansal et al / PRECURSOR B LYMPHOBLASTIC LEUKEMIA French-American-British (FAB) morphologic type of the lymphoblasts 11 and bone marrow blast percentages were recorded. In patients with lymph node and bone marrow involvement, more than 25% bone marrow blasts were required for the diagnosis of pb ALL, as opposed to fewer than 25% marrow blasts and fewer than 10% circulating blasts that would be classified as lymphoblastic lymphoma according to the Pediatric Oncology Group criteria. 12 Retrospective assessment for nuclear terminal deoxyribonucleotidyl transferase (TdT) enzyme could not be performed by flow cytometry because additional cryopreserved cell samples were not available for study. Therefore, an immunohistochemical stain for TdT (TdT, DAKO, Carpinteria, CA) was performed in all cases with available paraffin-embedded sections (cases 7, 10-15) or unstained air-dried marrow aspirate smears, using the DAKO automated staining system. 13 The aspirate smear slides were fixed in cold methanol (4 C, 15 minutes) before antigen retrieval. In all cases, a microwave oven (100 C, 14 minutes, Target Retrieval Solution [DAKO], ph ) was used for antigen retrieval. Conventional Cytogenetics and Fluorescence In Situ Hybridization Conventional cytogenetic analyses were performed on trypsin Wright stain banded bone marrow. 14 Cells were examined from 24- or 48-hour unstimulated cultures or from methotrexate-synchronized unstimulated cells cultured for 24 hours. At least 20 cells per case were examined whenever possible. Chromosomal abnormalities were described according to the International System for Human Cytogenetic Nomenclature (1995). 15 Fluorescence in situ hybridization (FISH) analyses were performed using commercially available (Vysis, Downers Grove, IL) α satellite centromeric and locus-specific rearrangement probes in 6 cases. At least 500 interphase nuclei were examined for FISH analysis. Results Clinical and Morphologic Features for 15 Patients The clinical and morphologic features for all patients are given in Table 1. The 15 patients included 9 children (cases 1-9, Table 1) with an age range of 11 months to 13 years (median, 5 years) and 6 adults (cases 10-15, Table 1) with an age range of 20 to 73 years (median, 60 years). All 15 patients were given a diagnosis of pb ALL by a multidisciplinary approach on referral to RPCI, with the unusual finding of surface light chain immunoglobulin restricted lymphoblasts by FCI analysis. The white blood cell counts at diagnosis ranged from 840 to 169,100/µL ( /L; median, 4,200/µL [ /L]). The corresponding Wright-Giemsa stained bone marrow aspirate smears were available for review in all cases. By FAB morphologic type, the blasts were L1 or L2 in all cases Image 1. Bone marrow blast percentages ranged from 38.5% to 97.4% (median, 91%) in the smear preparations. Enzyme cytochemical stains on smear preparations were Table 1 Clinical and Pathologic Features of 15 Patients With Precursor B Lymphoblastic Leukemia Sites Blasts Outcome Case No./Sex/ Spleen/ Mediastinum/ WBC FAB Time of CR/Duration Age (y) * LN Liver CNS Count (/µl ) BM (%) Type FCI Diagnosis (mo) Survival 1/F/3 No No/2-3 No/No 1, L1 Initial Yes/49 Alive; NED 2/M/3 Yes 2/2 No/No 59, L1 Initial Yes/17 Alive; NED 3/M/3 No No/No No/No 4, L2 Initial Yes/27 Alive; NED 4/F/5 No No/No No/No 4, L1 Initial Yes/21 Alive; NED 5/M/7 Yes No/No No/No 2, L2 Initial Yes/72 Alive; NED 6/M/9 No No/No No/No 2, L1 Initial Yes/25 Alive; NED 7/M/12 Yes No/4 No/No 169, L2 Initial No Died; 5 mo 8/M/11 mo Yes Tip/No No/Yes 22, L1 Initial Yes/57 Alive; NED 9/F/13 Yes No/2-3 No/No 13, L2 Initial Yes/19 Alive; NED 10/M/20 No No/No No/No 2, L1 Initial Yes/4 Died 11/M/34 Yes No/No No/No 1, L2 Initial Yes/1 Died 12/M/56 No No/No No/No 10, L2 Initial Yes/22 Alive; NED 13/F/62 No No/No No/No 7, L2 Relapse No Died 14/F/67 No No/No No/No 3, L2 Initial No Died 15/F/73 No No/No No/No L2 Relapse Yes/6 Died BM, bone marrow; CNS, central nervous system; CR, complete remission; FAB, French-American-British co-operative group 11 ; FCI, flow cytometric immunophenotypic analysis; LN, lymph nodes; NED, no evidence of disease. * Unless otherwise indicated. Numeric values are centimeters. Values are given in conventional units; to convert to Système International units ( 10 9 /L), multiply by The time of FCI (at initial diagnosis or relapse) that showed surface light chain immunoglobulin restriction on lymphoblasts. FCI at primary diagnosis and at persistent/relapsed leukemia in these cases showed surface light chain immunoglobulin restriction on lymphoblasts. 514 Am J Clin Pathol 2004;121: Downloaded 514 from

4 Hematopathology / ORIGINAL ARTICLE available for review for 10 patients (cases 1-6, 8, 9, 11, 12). By these cytochemical stains, the leukemic cells were negative for myeloperoxidase and Sudan black in smears from all 10 patients, negative for chloroacetate esterase in 9 of 9, and showed granular periodic acid Schiff positivity in 2% to 83% of blasts (median, 35%) in 9 of 9. Bone marrow trephine biopsies were performed in all adults, revealing effacement of marrow architecture by leukemic cells in all cases. Peripheral blood smears at the time of diagnostic bone marrow biopsies were available for review for 1 patient (case 12). One adult (case 11) underwent a concurrent lymph node biopsy at a local referring hospital at the time of diagnosis, which was reviewed (R.K. and M.B.) and showed architectural effacement by lymphoblasts that were revealed as CD10+TdT+ by paraffin section immunohistochemical stains. Fresh tissue from this lymph node was not submitted for FCI analysis. Bone marrow trephine biopsy sections in this case, however, showed extensive bilateral effacement of marrow architecture by lymphoblasts, consistent with pb ALL as opposed to precursor B lymphoblastic lymphoma by the Pediatric Oncology Group criteria. 12 FCI Analysis and TdT Immunohistochemical Findings for 15 Patients The flow cytometric immunophenotype for all patients is given in Table 2. The FCI analyses for all except 2 patients were performed at the time of initial diagnosis. For 1 adult (case 12), the initial FCI analysis was done at Buffalo General Hospital at diagnosis and was followed by repeated diagnostic FCI analysis at RPCI. The scatter plots of both FCI analyses for case 12 were reviewed (R.K. and C.C.S.) and showed the same surface light chain restriction on the lymphoblasts and additional dim surface IgM expression on the lymphoblasts in the initial analysis. For 1 adult (case 14), FCI analyses were done on 2 separate bone marrow aspirate samples at diagnosis and at the time of 5 subsequent analyses, all of which were performed at the RPCI flow cytometry laboratory and showed persistent leukemia. The same immunophenotype and surface light chain restriction were present in the first 5 of the 7 FCI analyses; the sixth and the seventh consecutive analyses did not show surface light chain restriction in this patient with persistent lymphoblastic leukemia. For 2 patients, the results of FCI analysis at the time of relapse showed surface light chain immunoglobulin restriction. Review of the FCI analysis results at the time of primary diagnosis in these 2 cases did not show surface light chain restriction on the lymphoblasts. The blasts were CD19+ in all cases and showed bright coexpression of CD19 and CD10 in samples from 14 of 15 patients. CD45 was dim or absent, with HLA-DR positivity in all cases. The leukemic cells were CD34+ by FCI analysis in 12 of 15 patients and TdT+ by immunohistochemical analysis in 8 of 8 Image 2. The 3 CD34 cases included 1 TdT+ case, 1 with t(1;19)(q23;p13), and 1 infant with 71.5% bone marrow lymphoblasts. Surface CD22 expression was present on the neoplastic cells in all cases and showed less fluorescence intensity than the residual benign B cells in the sample. CD20 expression was dim in 2 cases and absent in 13. Dim CD5 expression was noted in the sample from 1 infant with CD10+CD19+CD34+ blasts; all other cases were CD5. The surface light chain immunoglobulin expressed was κ in the samples from 12 of 15 patients and λ in 3 of 15, with dim fluorescence intensity in all cases. Samples from 4 patients were analyzed for surface heavy chain immunoglobulins (cases 5, 8, 12, and 14); 2 showed IgD dim +IgM lymphoblasts (cases 5 and 8); case 12 showed IgM+IgD lymphoblasts; and the neoplastic cells in case 14 were negative for IgD and IgM. Aberrant dim expression of a myeloid marker CD13 or CD33 was detected on the leukemic cells in 6 patients, with CD13+CD33+ lymphoblasts in the samples from 3 patients, CD13+CD33 lymphoblasts in 2, and CD13 CD33+ leukemic cells in 1. Examples of flow cytometry plots from pediatric and adult cases of surface light chain positive pb ALL are shown in Image 3, Image 4, Image 5, Image 6, Image 7, and Image 8. Conventional Cytogenetics and FISH Findings for 15 Patients Cytogenetic findings are summarized in Table 3. Karyotypic analyses were performed on samples from 12 patients, Image 1 Several lymphoblasts are present in this bone marrow smear from a 62-year-old woman (Wright-Giemsa, 1,000). Downloaded from Am J Clin Pathol 2004;121:

5 Kansal et al / PRECURSOR B LYMPHOBLASTIC LEUKEMIA Table 2 Flow Cytometric Immunophenotypic Features for 15 Patients With Precursor B Lymphoblastic Leukemia * Case No. TdT CD34 HLA-DR CD45 CD19 CD10 CD22 CD20 sig CD13 CD33 CD5 1 NA + + +(d) (d) λ(d) +(d) 2 NA + + +(d) + + +(d) κ(d) 3 NA + +(d) κ(d) +(d) (d) +(d) + +(d) +(d) κ(d) +(d) +(d) 5 NA (d) κ(d) 6 NA + + +(d) + + +(d) κ(d) +(d) +(d) (d) + + +(d) κ(d) +(d) +(d) 8 NA + +(d) κ(d) 9 NA + +(d) κ(d) (d) +(d) λ(d) (d) +(d) +(d) + + +(d) κ(d) (d) λ(d) +(d) (d) +(d) + + +(d) κ(d) (d) + + κ(d) +(d) (d) κ(d) NA, not available; sig, surface immunoglobulin; TdT, nuclear terminal deoxyribonucleotidyl transferase (by immunohistochemical stains); +, positive; (d), dim;, negative. * The samples for flow cytometric immunophenotypic analysis were bone marrow aspirates in all cases except case 12, for which a peripheral blood sample was used. Samples were diagnostic in all cases except 13 and 15, which were samples at relapse of sig precursor B-cell ALL. Flow cytometric immunophenotypic analysis was 4-color in all cases except 5, 8, and 14, in which it was 3-color. Surface IgD and IgM were analyzed in cases 5, 8, 12, and 14; see the text. abnormalities for 2 (cases 3 and 6) without an analyzable karyotype. FISH studies confirmed trisomies 4 and 10 in case 1, trisomies 4 and 21 in case 2, trisomy 12 in case 4, and bcr/abl fusion in case 7. In case 3, FISH analysis showed 2 clonal populations: one with trisomy 4 and the other with trisomies 4 and 10. A cryptic t(12;21)(p13;q22) was revealed by FISH in case 6 by using the TEL/AML1 locus-specific fusion probe. Image 2 Terminal deoxyribonucleotidyl transferase (TdT)+ lymphoblasts in paraffin-embedded core biopsy section (TdT, immunohistochemical stain, 400). but samples were not analyzable for the remaining 3 patients (cases 3, 6, and 15) owing to inadequate mitoses or a hypocellular specimen. The karyotypes in the 12 analyzable cases were negative for an 8q24 (myc) rearrangement. The dividing cells showed t(1;19)(q23;p13) in 3 patients, t(9;22)(q34;q11) in 1 patient, t(2;11)(p21;q23) in 1 patient, trisomy 12 in 1 patient, hyperdiploidy in 3 patients, and a normal karyotype in 3 patients. FISH studies were performed on the samples from 6 patients. These studies confirmed karyotypic findings for 4 patients and provided evidence of specific cytogenetic Multiparametric Correlation in 9 Pediatric Cases The 9 children in our study (cases 1-9) included 6 boys and 3 girls, with ages ranging from 11 months to 13 years (median, 5 years). The total leukocyte counts at diagnosis ranged from 1,400 to 169,100/µL ( /L; median, 4,200/µL [ /L]). The diagnostic bone marrow aspirate samples from all pediatric cases were obtained at diagnosis. The lymphoblasts in all cases showed FAB L1 or L2 morphologic features on Wright-Giemsa stained bone marrow aspirate smears. Bone marrow blast percentages ranged from 59.6% to 97.4% (median, 95.8%). Bone marrow trephine core biopsies were not performed on any of the children. Regrettably, marrow aspirate clots or evaluable TdT-stained aspirate smears were available for only 2 children; immunohistochemical analysis showed TdT+ lymphoblasts in these 2 cases. FCI analysis of the samples from all patients revealed lymphoblasts with bright coexpression of CD19 and CD10, with surface κ light chain restriction for all except 1 patient with λ light chain restriction (case 1). This patient was a 3- year-old boy with CD5 dim +CD10+CD19+CD20 dim +CD34+, surface λ+ lymphoblasts, and this seems to be the first 516 Am J Clin Pathol 2004;121: Downloaded 516 from

6 Hematopathology / ORIGINAL ARTICLE 120 Side Scatter Forward Scatter Side Scatter Anti HLA-DR PerCP CD19PE CD19 PE CD22 TC CD34 APC CD10 PC CD20 FITC κ APC CD19 PC CD19 PC κ APC Image 3 (Case 2) Surface immunoglobulin positive precursor B lymphoblastic leukemia in a 3-year-old boy with CD45 dim + HLA-DR+CD10+CD19+CD22 dim +CD34+ surface κ dim + leukemic cells (arrows) at diagnosis (4-color flow cytometric immunophenotypic analysis). Sparse residual benign B cells are present in this case (arrowheads). Note that the color assigned to the neoplastic cells varies in different tubes. APC, allophycocyanin; FITC, fluorescein isothiocyanate; PC, PE-cyanin-5; PE, phycoerythrin; PerCP, peridinium chlorophyll protein complex; TC, Tricolor (Caltag, Burlingame, CA). reported pediatric case of a CD5+ pb ALL with sig light chain restriction revealed by FCI analysis. Owing to the coexpression of CD5 and CD19 with surface λ, which is more common than κ in mantle cell lymphoma, 2 the unlikely possibility of the blastoid variant of mantle cell lymphoma in a child was considered but rejected owing to the unequivocal presence of CD34 in FCI analysis and a karyotype characteristic of pb ALL without the t(11;14) translocation, in addition to the dim expression of CD45, CD20, and surface immunoglobulin by FCI analysis that argue against a diagnosis of mantle cell lymphoma. For 1 child (case 4) with CD10+CD19+CD34+HLA- DR+, surface κ+ blasts, trisomy 12 was revealed as the sole karyotypic abnormality. Our pediatric cases also included cases with a cryptic t(12;21) translocation, TEL/AML1 fusion 16 (n = 1), t(9;22)(q34;q11), bcr/abl fusion 17 (n = 1), and a hyperdiploid karyotype (n = 3). 18 Two children in our study had the t(1;19)(q23;p13) translocation, which often is associated with a late stage of precursor B-cell differentiation that shows cytoplasmic IgM expression with or without surface IgM but no surface light chain expression. 19,20 The lymphoblasts in samples from 1 of 2 patients with the t(1;19) showed dim surface IgD κ expression, in the absence of surface IgM expression by FCI analysis. Dim surface IgD without surface IgM by FCI analysis also was present in 1 infant with CD10+CD19+CD20 CD22+CD34 HLA-DR+ blasts that correspond to an intermediate stage of B- lymphoblast differentiation. The 9 children were treated according to the Pediatric Oncology Group chemotherapy protocols. All patients Downloaded from Am J Clin Pathol 2004;121:

7 Kansal et al / PRECURSOR B LYMPHOBLASTIC LEUKEMIA 120 Side Scatter Forward Scatter Side Scatter Anti HLA-DR PerCP CD19PE CD19 PE CD34 APC CD10 PC κ APC CD19 PC CD19 PC κ APC CD22 TC CD34 TC CD20 FITC CD33 PC Image 4 (Case 3) Surface immunoglobulin positive precursor B lymphoblastic leukemia in a 3-year-old boy with CD45 HLA- DR+CD10+CD19+CD22+CD34+ surface κ dim + leukemic cells (arrows) at diagnosis (4-color flow cytometric immunophenotypic analysis). The fluorescence intensity of CD22 on the neoplastic cells, although brighter than the CD22 intensity observed in case 2 (Image 3), is less than that of the admixed benign B cells, which are polytypic by surface light chain immunoglobulin expression (arrowheads). Also shown is the dim aberrant expression of CD33 on the neoplastic cells. Note that the color assigned to the neoplastic cells varies in different tubes. APC, allophycocyanin; FITC, fluorescein isothiocyanate; PC, PE-cyanin- 5; PE, phycoerythrin; PerCP, peridinium chlorophyll protein complex; TC, Tricolor (Caltag, Burlingame, CA). except 1 achieved complete remission and were alive with no evidence of disease at 17 to 72 months (median, 26 months) following complete remission. Multiparametric Correlation in 6 Adult Cases The 6 adults in our study (cases 10-15) included 3 men and 3 women, with ages ranging from 20 to 73 years 518 Am J Clin Pathol 2004;121: Downloaded 518 from

8 Hematopathology / ORIGINAL ARTICLE 120 Side Scatter Forward Scatter Side Scatter Anti HLA-DR PerCP CD19PE CD19 PE CD22 TC CD34 APC CD10 PC CD20 FITC κ APC CD19 PC CD19 PC κ APC Image 5 (Case 6) Surface immunoglobulin positive precursor B lymphoblastic leukemia in a 9-year-old boy with CD45 dim +HLA- DR+CD10+CD19+CD22 dim +CD34+ surface κ dim + leukemic cells (arrows) at diagnosis (4-color flow cytometric immunophenotypic analysis). Residual benign B cells (arrowheads) show brighter CD22 expression in comparison with the leukemic cells. Note that the color assigned to the neoplastic cells varies in different tubes. APC, allophycocyanin; FITC, fluorescein isothiocyanate; PC, PE-cyanin-5; PE, phycoerythrin; PerCP, peridinium chlorophyll protein complex; TC, Tricolor (Caltag, Burlingame, CA). (median, 59 years). The total leukocyte counts at diagnosis ranged from 840 to 10,980/µL ( /L; median, 2,630/µL [ /L]). The leukemic samples with surface light chain immunoglobulin restriction were obtained at diagnosis from 4 patients and at relapse from 2 patients. The lymphoblasts in samples from all patients showed FAB L1 or L2 morphologic features on Wright-Giemsa stained marrow aspirate smears. Bone marrow blast percentages ranged from 38.5% to 97.0% (median, 61.3%). Immunoperoxidase stains performed on paraffin-embedded trephine core biopsy or marrow aspirate clot sections revealed that the leukemic cells were TdT+ in all cases. By FCI analysis, the leukemic cells coexpressed CD10 and CD19 in samples from all patients except 1 (case 14) with an CD10 CD15 CD19+CD22+CD20 CD34+TdT+ immunophenotype, which corresponded to an early stage of precursor B-cell differentiation. Surface IgM and IgD were not detectable by FCI analysis in this case, which showed the t(2;11)(p21;q23) translocation by karyotypic analysis. Surface IgM was present in 1 patient (case 12) with sig+ results but without a karyotypic abnormality. Surface heavy chain immunoglobulins were not analyzed in the sample from the patient (case 10) with the t(1;19)(q23;p13). In the 2 patients with surface light chain expressing lymphoblasts at relapse, review of the initial FCI analysis did not show surface light chain expression on the leukemic cells at primary diagnosis. Two patients (cases Downloaded from Am J Clin Pathol 2004;121:

9 Kansal et al / PRECURSOR B LYMPHOBLASTIC LEUKEMIA 120 Side Scatter Forward Scatter Side Scatter Anti HLA-DR PerCP CD19PE CD19 PE CD22 TC CD34 APC CD10 PC CD20 FITC κ APC CD19 PC CD19 PC κ APC CD13 PE CD13 PE CD34 APC CD19 APC CD34 APC CD33 PC Image 6 (Case 7) Surface immunoglobulin positive precursor B lymphoblastic leukemia in a 12-year-old boy with CD45 dim +HLA-DR+CD10+CD19+CD22 dim +CD34+ surface κ dim + leukemic cells (arrows) at diagnosis (4-color flow cytometric immunophenotypic analysis). Also shown is the dim aberrant expression of the myeloid markers, CD13 and CD33, on the neoplastic cells in this case. Note that the color assigned to the neoplastic cells varies in different tubes. APC, allophycocyanin; FITC, fluorescein isothiocyanate; PC, PE-cyanin-5; PE, phycoerythrin; PerCP, peridinium chlorophyll protein complex; TC, Tricolor (Caltag, Burlingame, CA). 10 and 14) showed surface light chain restricted lymphoblasts at initial diagnosis and at subsequent FCI analyses to detect residual or relapsed leukemia. In case 14, this surface light chain immunoglobulin expression contributed to the immunophenotypic fingerprint of the leukemic cells in 3 FCI analyses performed for residual leukemia and was no longer detectable in the fourth and fifth consecutive FCI analyses for persistent disease. All adults received chemotherapy according to the Cancer and Leukemia Group B protocols. Of the 6 patients, 4 achieved complete remission, with a duration ranging from 41 days to 666 days; however, 5 of 6 did not survive. 520 Am J Clin Pathol 2004;121: Downloaded 520 from

10 Hematopathology / ORIGINAL ARTICLE 120 Side Scatter Forward Scatter Side Scatter Anti HLA-DR PerCP CD19PE CD19 PE 101 CD34 APC CD10 PC κ APC CD19 PC CD19 PC κ APC Image 7 (Case 10) Surface immunoglobulin positive precursor B lymphoblastic leukemia in a 20-year-old man with CD45 dim +HLA-DR+CD10+CD19+CD34 surface λ dim + leukemic cells (arrows) at diagnosis (4-color flow cytometric immunophenotypic analysis). Note that the color assigned to the neoplastic cells varies in different tubes. APC, allophycocyanin; PC, PE-cyanin-5; PE, phycoerythrin; PerCP, peridinium chlorophyll protein complex. Discussion Accurate diagnostic distinction between pb ALL and mature B-cell leukemia (Burkitt leukemia) is critical for disease management. Burkitt leukemia typically shows FAB L3 morphologic features, has a mature B-cell phenotype (CD34 TdT, surface light chain+) by FCI analysis and the c-myc gene rearrangement by cytogenetics, and manifests clinically with bulky disease that requires more intensive chemotherapy than standard ALL therapy, with central nervous system prophylaxis. 21 However, discrepancies in the morphologic features and immunophenotype of Burkitt leukemia have been described. Hammami et al 22 reported 9 cases of mature B-cell ALL with FAB L1 or L2 morphologic features. Navid et al 23 reported 5 pediatric cases of Burkitt leukemia, which originally were misinterpreted as pb ALL owing to the absence of sig by FCI analysis. Coexpression of precursor cell markers CD34 and TdT also has been reported in Burkitt leukemia In all of the aforementioned cases with an aberrant immunophenotype or morphologic features, the critical feature that determined the course of the disease as Burkitt leukemia was the c-myc gene translocation. All patients in our study were given a diagnosis of pb ALL by a multidisciplinary approach, and they represent pb ALL cases with morphologic and cytogenetic features typical of this entity but with unexpected surface light chain immunoglobulin restriction revealed by FCI analysis. Our pediatric cases included cases with a cryptic t(12;21) translocation, TEL/AML1 fusion, 16 t(9;22)(q34;q11), bcr/abl fusion, 17 and a hyperdiploid karyotype. 18 These cytogenetic abnormalities are different from those reported in the 4 cases of sig+ pb ALL identified in a large study of pediatric pb ALLs. 5 One of our pediatric cases also showed trisomy 12, which reportedly is uncommon in precursor B-cell neoplasms, 27,28 although it often is associated with B-cell Downloaded from Am J Clin Pathol 2004;121:

11 Kansal et al / PRECURSOR B LYMPHOBLASTIC LEUKEMIA 120 Side Scatter Forward Scatter Side Scatter Anti HLA-DR PerCP CD19PE CD19 PE CD22 TC CD34 APC CD10 PC CD20 FITC κ APC CD19 PC CD19 PC κ APC Image 8 (Case 13) Surface immunoglobulin positive precursor B lymphoblastic leukemia in a 62-year-old woman with CD45 dim +HLA-DR+CD10+CD19+CD22 dim +CD34+ surface κ dim + leukemic cells (arrows) at relapse (4-color flow cytometric immunophenotypic analysis). Note that the color assigned to the neoplastic cells varies in different tubes. APC, allophycocyanin; FITC, fluorescein isothiocyanate; PC, PE-cyanin-5; PE, phycoerythrin; PerCP, peridinium chlorophyll protein complex; TC, Tricolor (Caltag, Burlingame, CA). chronic lymphocytic leukemia, 29 a neoplasm of mature B cells. Of interest, trisomy 12 was reported previously in 2 adult cases of sig+ pb ALL. In 1 case, it was part of a complex karyotype in a 23-year-old man with CD9+CD10+CD24+HLA-DR+TdT+, surface IgMλ+ lymphoblasts with non FAB L3 morphologic features. 6 In our case with trisomy 12, dim aberrant expression of CD13 and CD33 also was present; these markers were not analyzed in the case reported by Michiels and colleagues. 6 Vasef and colleagues 7 reported the second adult case of sig+ pb ALL with trisomy 12. The immunophenotype in their case, however, was CD5+CD10 CD19+CD20+CD34 TdT+, surface λ+, in contrast with our case that was CD5 CD10+CD19+CD20 CD22+CD34+, surface κ+. The immunologic classification of ALL of B-cell lineage is based on the stages of maturation of a B cell, with pb ALL arising from the early, intermediate, and late precursor stages of B-cell differentiation. 1-3,21 In addition to nuclear TdT and HLA-DR that are expressed by B lymphoblasts at all precursor stages of maturation, the earlystage blasts express CD19 and cytoplasmic CD22 and are CD10. 1,21 The intermediate-stage B lymphoblasts also express CD10, and the late precursor stage is characterized by the expression of cytoplasmic heavy chain immunoglobulin IgM. 1,21 All 6 adult pb ALL cases with surface light chain expression described by Vasef et al 7 seemed to have an immunophenotype consistent with the most mature precursor B-cell stage, and it was suggested that the immunophenotype in these sig+ pb ALL cases was intermediate between that of pre B cells, which are TdT+ and cytoplasmic Ig+, and mature B cells, which express surface heavy and light chain immunoglobulins. 6,7 Our study cohort of pb ALL included 522 Am J Clin Pathol 2004;121: Downloaded 522 from

12 Hematopathology / ORIGINAL ARTICLE Table 3 Cytogenetic Findings for 15 Patients With Precursor B Lymphoblastic Leukemia Case No. Karyotype Comments ,inc [2 cells]/46,xx [1 cell] FISH +4, ,XY,+X,+4,+6,+14,+21,+21 [20 cells] FISH +4,+21 3 Not analyzable FISH +4/+4, ,XX,?+12,inc [2 cells]/46,xx [15 cells] FISH ,XY,t(1;19)(q23;p13),i(7)(q10),inc [3 cells]/46,xy [17 cells] 6 Not analyzable FISH t(12;21)(p13;q22),tel/aml1 fusion 7 46,XY,ider(9)(q10)t(9;22)(q34;q11),der(22)t(9;22) [19 cells]/48,xy,t(9;22)(q34;q11), FISH bcr/abl fusion +21,+der(22)t(9;22) [1 cell] 8 46,XY [4 cells] Hypocellular specimen 9 46,XX,t(1;19)(q23;p13) [15 cells] / 46,XX [5 cells] 7,XY,+5,der(19)t(1;19)(q23;p13) [19 cells]/47,idem, 3,+8 [1 cell] 11 45,XY,?inv(10), 20 [14 cells]/46,xy [6 cells] 12 46,XY [20 cells] 13 46,XX [20 cells] 14 46,XX,t(2;11)(p21;q23) [20 cells] 15 Not analyzable Hypocellular specimen FISH, Fluorescence in situ hybridization. cases in the early, intermediate, and late stages of precursor B-cell differentiation and demonstrated, for the first time, that surface light chain immunoglobulin restriction in pb ALL might be present in neoplasms arising from all (early, intermediate, and late) stages of a precursor B-cell, which otherwise have typical morphologic and cytogenetic features of pb ALL. Neoplastic pb cells (lymphoblasts) show aberrant surface marker expression and deviation from the normal sequence of maturation that can help to differentiate them from normal marrow progenitor B cells (hematogones), 30,31 which also can coexpress TdT and CD We have not systematically assessed the expression of surface light chain immunoglobulins on normal hematogones in our study. Nevertheless, the neoplastic cells in our cases provide an additional example of deviation from the normal sequence of B-cell maturation by showing unexpected surface light chain immunoglobulin expression, which likely would not be present in normal hematogones. Studies of normal B- lymphocyte development 32 have suggested subtle differences between the developmental stages identified in models of normal bone marrow compared with those deduced from B- lineage leukemias. 33 The expression of surface light chains on precursor B lymphoblasts in our study further suggests that it is not always possible to correlate leukemic B cells with normal B-cell developmental stages. One possible mechanism that would explain the occurrence of sig in this heterogeneous group of pb ALL cases is uncoupling of proliferation and maturation in B cells, which has been reported to occur in this group of neoplasms. 34 The expression of surface IgD in 2 (50%) of 4 of our cases, instead of surface IgM that might be present in transitional pre B-cell ALL, 4,20 also is likely an example of aberrant surface antigen expression in neoplastic B-lineage cells. The acquisition of surface CD22 often is considered to indicate a more mature precursor B-cell stage. This may lead to the argument that the presence of surface CD22 on neoplastic cells in all our cases suggests that these actually are examples of a more mature or transitional pb ALL. There are at least 2 reasons that do not support this view. First, the detection of surface CD22 on B-lineage lymphoblasts most likely is fluorochrome-dependent and has been reported in virtually all pb ALLs in at least 3 studies Furthermore, in the flow cytometry laboratory at RPCI, all sig pb ALL cases also show surface CD22 positivity, similar to our sig+ pb ALL cases (unpublished observation, C.C.S.), indicating that the surface CD22 positivity in our cases cannot be interpreted as evidence of a more mature stage of precursor B-cell maturation. Second, the interpretation that these cases represent a specific precursor stage of B-cell development is not supported by the cytogenetic findings in our cases, which include findings considered to be typically associated with the early-, intermediate-, and late-stage precursor B-cell ALL groups. Instead, it is possible that these sig+ ALL cases arise when a subset of leukemic cells within a typical sig ALL, whether early, intermediate, or late pre B-cell stage, progress toward greater maturational status and eventually become the predominant clone. Such a mechanism might also explain the 2 sig+ cases in our series that were detected only at relapse. Nevertheless, regardless of the underlying mechanism, these cases show that if surface light chain restriction is detected in a neoplastic B-cell population, it does not necessarily indicate a classification of a mature B-cell lymphoma/leukemia. In other words, a precursor B neoplasm cannot be ruled out solely by the presence of surface light chain immunoglobulin restriction on neoplastic cells by using FCI analysis. Downloaded from Am J Clin Pathol 2004;121:

13 Kansal et al / PRECURSOR B LYMPHOBLASTIC LEUKEMIA Information from systematic studies of pb ALL that have assessed surface light chain immunoglobulin expression on B lymphoblasts is limited. Behm and colleagues 5 reported 4 (0.7%) of 551 pediatric pb ALL cases with weak surface IgM and λ positivity. To the best of our knowledge, the published reports of sig+ pb ALL in adults include a case report 6 and retrospectively identified random cases. 7 Besides, the expression of surface light chain immunoglobulins on pb cells has not been evaluated in most recent large studies with focus on FCI evaluation of benign and neoplastic pb cells. 31,38,39 Although the incidence of sig+ pb ALL in our cases cannot be ascertained from our present data, this unusual expression of sig on precursor B lymphoblasts seems to be more frequent in our cases than currently reported in pb ALL. Furthermore, within a period of 8 months after we closed our study, we identified 3 additional patients given a diagnosis of sig+ pb ALL at RPCI (not included in this report). However, we do not have any further explanation for the apparently increased occurrence of sig+ pb ALL in our cases compared with the cases at most other tertiary institutions. From a diagnostic standpoint, our cases demonstrate that the expression of surface light chain immunoglobulins on neoplastic B cells does not necessarily indicate a mature B-cell phenotype, further emphasizing the need for a multiparametric approach in the differential diagnosis of B-cell neoplasms, including Burkitt leukemia vs precursor B lymphoblastic leukemia, and leukemic mantle cell lymphoma vs pb ALL. While the c-myc gene rearrangement would point to Burkitt leukemia in the differential diagnosis of pb ALL from Burkitt, the differential diagnosis of sig+ pb ALL from a leukemic manifestation of a mature B-cell lymphoma such as the blastoid variant of mantle cell lymphoma would be facilitated by the absence of the progenitor cell markers CD34 and TdT in the latter 40 ; the typically bright expression of CD20, CD45, and surface light chain immunoglobulin in FCI analysis in the latter; and the presence of the t(11;14) translocation by cytogenetic analysis or cyclin D1 expression by immunohistochemical analysis in the latter. 40 Furthermore, the expression of surface light chain immunoglobulins on B-lineage lymphoblasts might be of particular relevance in diagnosis when a limited antibody panel must be used for FCI analysis and indicates the need for caution in the classification of B-cell neoplasms by FCI analysis in such instances. The significance of this immunophenotypic finding in the clinical course of pb ALL is not clearly determined from our study. Nevertheless, in cases with sig+ lymphoblasts, the expression of sig light chains might contribute to the diagnostic immunophenotypic fingerprint of the neoplastic cells, as illustrated in 2 of our cases. This immunophenotypic finding also might appear for the first time at relapse in a typical pb ALL, as we noted in 2 cases. We draw the following conclusions from our study: (1) Surface light chain immunoglobulin restriction in pb ALL might be more common than currently recognized. (2) When present in pb ALL, it is not confined to a late precursor stage of B-cell differentiation, as previously suggested. Instead, it might be present in neoplasms arising from the early, intermediate, and late stages of a precursor B cell, which otherwise have typical morphologic and cytogenetic features of pb ALL. (3) The significance of this finding in the clinical course of pb ALL remains to be determined. (4) From a diagnostic standpoint, the presence of surface light chain restriction on neoplastic B cells by FCI analysis does not necessarily indicate a mature B-cell phenotype, emphasizing the need for caution in evaluating limited FCI antibody panels and the importance of multiparametric correlation in the immunophenotypic diagnosis and classification of B- lineage neoplasms. From the 1 Department of Pathology, Buffalo General Hospital, the State University of New York at Buffalo; Departments of 2 Pathology, 3 Medicine, and 4 Pediatrics, the 5 Clinical Cytogenetics Laboratory, and the 6 Laboratory of Flow Cytometry, Roswell Park Cancer Institute, Buffalo, NY. Address reprint requests to Dr Kansal: Dept of Pathology, Medical College of Wisconsin, 9200 W Watertown Plank Rd, Milwaukee, WI Acknowledgments: We thank Sally Bialy for assistance with retrieval of the flow cytometry data, Mary Beth Dell for assistance with the flow cytometry illustrations, and Bertram Schnitzer, MD, for reviewing the manuscript. References 1. Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue. Lyon, France: IARC Press; 2001: World Health Organization Classification of Tumours. 2. Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood. 1997;90: Foon KA, Todd RF. Immunologic classification of leukemia and lymphoma. Blood. 1986;68: Koehler M, Behm FG, Shuster J, et al. Transitional pre B-cell acute lymphoblastic leukemia of childhood is associated with favorable prognostic clinical features and an excellent outcome: a Pediatric Oncology Group study. Leukemia. 1993;7: Behm FG, Head DR, Pui C-H, et al. B-precursor ALL with unexpected expression of surface immunoglobulin (sig) mu and lambda [abstract]. Lab Invest. 1995;72:106A. 6. Michiels JJ, Adriaansen HJ, Hagemeijer A, et al. TdT positive B-cell acute lymphoblastic leukemia (B-ALL) without Burkitt characteristics. Br J Haematol. 1988;68: Vasef MA, Brynes RK, Murata-Collins JL, et al. Surface immunoglobulin light chain positive acute lymphoblastic leukemia of FAB L1 or L2 type: a report of 6 cases in adults. Am J Clin Pathol. 1998;110: Am J Clin Pathol 2004;121: Downloaded 524 from

14 Hematopathology / ORIGINAL ARTICLE 8. Stewart CC, Stewart SJ. Cell preparation for the identification of leukocytes. In: Darzynkiewicz Z, Crissman H, Robinson JP, eds. Methods in Cell Biology. New York, NY: Academic Press; 2001: Stewart CC, Stewart SJ. Multiparameter data acquisition and analysis of leukocytes by flow cytometry. In: Darzynkiewicz Z, Crissman H, Robinson JP, eds. Methods in Cell Biology. New York, NY: Academic Press; 2001: Riedy MC, Muirhead KA, Jensen CP, et al. Use of a photolabeling technique to identify nonviable cells in fixed homologous or heterologous cell populations. Cytometry. 1991;12: Bennett JM, Catovsky D, Daniel M-T, et al, for the French- American-British (FAB) co-operative group. Proposals for the classification of acute leukemias. Br J Haematol. 1976;33: Griffith RC, Kelly DR, Nathwani BN, et al. A morphologic study of childhood lymphoma of the lymphoblastic type: the Pediatric Oncology Group experience. Cancer. 1987;59: Chilosi M, Pizzolo G. Review of terminal deoxynucleotidyl transferase: biological aspects, methods of detection, and selected diagnostic applications. Appl Immunohistochem. 1995;3: Yunis JJ. New chromosome techniques in the study of human neoplasia. Hum Pathol. 1981;12: Mitelman F, ed. ISCN 1995: An International System for Human Cytogenetic Nomenclature Basel, Switzerland: S Karger; Rubnitz JE, Downing JR, Pui C-H, et al. TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol. 1997;15: Crist W, Carroll A, Shuster J, et al. Philadelphia chromosome positive acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome: a Pediatric Oncology Group study. Blood. 1990;76: Pui C-H, Crist WM, Look AT. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood. 1990;76: Raimondi SC, Behm FG, Roberson PK, et al. Cytogenetics of pre B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19). J Clin Oncol. 1990;8: Borowitz MJ, Hunger SP, Carroll AJ, et al. Predictability of the t(1;19)(q23;p13) from surface antigen phenotype: implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: a Pediatric Oncology Group study. Blood. 1993;82; Silverman LB, Sallan SE. Acute lymphoblastic leukemia. In: Handin RI, Lux SE, Thomas P, eds. Blood: Principles and Practice of Hematology. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003: Hammami A, Chan WC, Michels SD, et al. Mature B-cell acute leukemia: a clinical morphological, immunological, and cytogenetic study of nine cases. Hematol Pathol. 1991;5: Navid F, Mosijczuk AD, Head DR, et al. Acute lymphoblastic leukemia with the (8;14)(q24;q23) translocation and FAB L3 morphology associated with a precursor immunophenotype: the Pediatric Oncology Group experience. Leukemia. 1999;13: Drexler HG, Messmore HL, Menon M, et al. A case of TdTpositive B-cell acute lymphoblastic leukemia. Am J Clin Pathol. 1986;85: Secker-Walker L, Stewart E, Norton J, et al. Multiple chromosome abnormalities in a drug resistant TdT positive B- cell leukemia. Leuk Res. 1987;11: Shende A, Festa RS, Wedgwood JF, et al. A paediatric case of a TdT positive B-cell acute lymphoblastic leukaemia (B-ALL) without Burkitt characteristics [letter]. Br J Haematol. 1988;70: Oshimura M, Freeman AI, Sandberg AA. Chromosomes and causation of human cancer and leukemia, XXVI: banding studies in acute lymphoblastic leukemia (ALL). Cancer. 1977;40: Palka G, Fioritoni G, Lambardo M, et al. A cytogenetic survey of 13 patients with acute lymphocytic leukemia (ALL). Hematologica. 1987;72: Matutes E, Oscier D, Garcia-Marco J, et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol. 1996;92: Rimsza LM, Larson RS, Winter SS, et al. Benign hematogone-rich lymphoid proliferations can be distinguished from B-lineage acute lymphoblastic leukemia by integration of morphology, immunophenotype, adhesion molecule expression, and architectural features. Am J Clin Pathol. 2000;114: McKenna RW, Washington LT, Aquino DB, et al. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4- color flow cytometry. Blood. 2001;98: Loken MR, Shah VO, Dattilio KL, et al. Flow cytometric analysis of human bone marrow, II: normal B lymphocyte development. Blood. 1987;70: Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B-cell associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984;63: Hurwitz C, Loken MR, Graham ML, et al. Asynchronous antigen expression in B lineage acute lymphoblastic leukemia. Blood. 1988;72: Boue DR, LeBien TW. Expression and structure of CD22 in acute leukemia. Blood. 1988;71: Dorvault CC, Jones PA, Swerdlow SH, et al. Frequent cell surface expression of CD22 on B-lineage acute lymphoblastic leukemias (ALL) [abstract]. Lab Invest. 1999;79:135A. 37. Siebert JD, Katzke KA, Copp MV, et al. Cell surface CD22 is commonly expressed in precursor B-lymphoblastic leukemia [abstract]. Am J Clin Pathol. 2001;116: Ciudad J, San Miguel JF, Lopez-Berges MC, et al. Detection of abnormalities in B-cell differentiation pattern is a useful tool to predict relapse in precursor-b-all. Br J Haematol. 1999;104: Weir EG, Cowan K, LeBeau P, et al. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four-color flow cytometry: implications for residual disease detection. Leukemia. 1999;13: Soslow RA, Zukerberg LR, Harris NL, et al. bcl-1 (PRAD- 1/cyclin D-1) overexpression distinguishes the blastoid variant of mantle cell lymphoma from B-lineage lymphoblastic lymphoma. Mod Pathol. 1997;10: Downloaded from Am J Clin Pathol 2004;121:

Significant CD5 Expression on Normal Stage 3 Hematogones and Mature B Lymphocytes in Bone Marrow

Significant CD5 Expression on Normal Stage 3 Hematogones and Mature B Lymphocytes in Bone Marrow Hematopathology / CD5 Expression on Normal B Cells Significant CD5 Expression on Normal Stage 3 Hematogones and Mature B Lymphocytes in Bone Marrow Franklin S. Fuda, DO, Nitin J. Karandikar, MD, PhD, and

More information

CME/SAM. Flow Cytometric Immunophenotyping of Cerebrospinal Fluid Specimens

CME/SAM. Flow Cytometric Immunophenotyping of Cerebrospinal Fluid Specimens Hematopathology / Flow Cytometric Immunophenotyping of CSF Specimens Flow Cytometric Immunophenotyping of Cerebrospinal Fluid Specimens Fiona E. Craig, MD, 1 N. Paul Ohori, MD, 2 Timothy S. Gorrill, MD,

More information

Case 3. Ann T. Moriarty,MD

Case 3. Ann T. Moriarty,MD Case 3 Ann T. Moriarty,MD Case 3 59 year old male with asymptomatic cervical lymphadenopathy. These images are from a fine needle biopsy of a left cervical lymph node. Image 1 Papanicolaou Stained smear,100x.

More information

Bumps on the Neck and Groin of a 2-Year-Old Male. Laboratory Findings: Table 1, Table 2; Figure 1; Image 1, Image 2, Image 3

Bumps on the Neck and Groin of a 2-Year-Old Male. Laboratory Findings: Table 1, Table 2; Figure 1; Image 1, Image 2, Image 3 Bumps on the Neck and Groin of a 2-Year-Old Male 1 Erikakelly Strand, BS* Clinical History Patient: 2-year-old white male. Chief Complaint: Bumps on neck and groin. History of Present Illness: A 2-year-old

More information

Diagnostic challenge: Acute leukemia with biphenotypic blasts and BCR-ABL1 translocation

Diagnostic challenge: Acute leukemia with biphenotypic blasts and BCR-ABL1 translocation Case Study Diagnostic challenge: Acute leukemia with biphenotypic blasts and BCR-ABL1 translocation Ling Wang 1 and Xiangdong Xu 1,2,* 1 Department of Pathology, University of California, San Diego; 2

More information

Differential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital

Differential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Differential diagnosis of hematolymphoid tumors composed of medium-sized cells Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Lymphoma classification Lymphoma diagnosis starts with morphologic

More information

Successful flow cytometric immunophenotyping of body fluid specimens

Successful flow cytometric immunophenotyping of body fluid specimens Successful flow cytometric immunophenotyping of body fluid specimens Fiona E. Craig, MD Division of Hematopathology Mayo Clinic Arizona 2017 MFMER slide-1 Financial disclosure No conflicts 2017 MFMER slide-2

More information

CME/SAM. Olga Pozdnyakova, MD, PhD, 1 Svetlana Kondtratiev, MD, 1,2 Betty Li, MS, 1 Karry Charest, 1 and David M. Dorfman, MD, PhD 1.

CME/SAM. Olga Pozdnyakova, MD, PhD, 1 Svetlana Kondtratiev, MD, 1,2 Betty Li, MS, 1 Karry Charest, 1 and David M. Dorfman, MD, PhD 1. Hematopathology / New Mastocytosis Flow Cytometry Approach High-Sensitivity Flow Cytometric Analysis for the Evaluation of Systemic Mastocytosis Including the Identification of a New Flow Cytometric Criterion

More information

ABERRANT EXPRESSION OF CD19 AND CD43

ABERRANT EXPRESSION OF CD19 AND CD43 ABERRANT EXPRESSION OF CD19 AND CD43 IN A PATIENT WITH THERAPY-RELATED ACUTE MYELOID LEUKEMIA AND A HISTORY OF MANTLE CELL LYMPHOMA Yen-Chuan Hsieh, 1 Chien-Liang Lin, 2 Chao-Jung Tsao, 2 Pin-Pen Hsieh,

More information

Classification of Hematologic Malignancies. Patricia Aoun MD MPH

Classification of Hematologic Malignancies. Patricia Aoun MD MPH Classification of Hematologic Malignancies Patricia Aoun MD MPH Objectives Know the basic principles of the current classification system for hematopoietic and lymphoid malignancies Understand the differences

More information

Flow Cytometric Analysis of Surface Light Chain Expression Patterns in B-Cell Lymphomas Using Monoclonal and Polyclonal Antibodies

Flow Cytometric Analysis of Surface Light Chain Expression Patterns in B-Cell Lymphomas Using Monoclonal and Polyclonal Antibodies Hematopathology / Light Chain Expression in B-NHLs Flow Cytometric Analysis of Surface Light Chain Expression Patterns in B-Cell Lymphomas Using Monoclonal and Polyclonal Antibodies Pedro Horna, MD, Horatiu

More information

Immunophenotypic Profile of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia

Immunophenotypic Profile of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Hematopathology / IMMUNOPHENOTYPE OF LPL/WM Immunophenotypic Profile of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Sergej Konoplev, MD, PhD, L. Jeffrey Medeiros, MD, Carlos E. Bueso-Ramos,

More information

The spectrum of flow cytometry of the bone marrow

The spectrum of flow cytometry of the bone marrow The spectrum of flow cytometry of the bone marrow Anna Porwit Lund University Faculty of Medicine Dept. of Clinical Sciences Div. Oncology and Pathology anna.porwit@med.lu.se Disclosure of speaker s interests

More information

Citation International Journal of Hematology, 2013, v. 98 n. 4, p The original publication is available at

Citation International Journal of Hematology, 2013, v. 98 n. 4, p The original publication is available at Title Diagnostic challenges in a case of B cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma Author(s) So, JCC; Yung, KH; Chu, ML; Wan,

More information

Lack of Surface Immunoglobulin Light Chain Expression by Flow Cytometric Immunophenotyping Can Help Diagnose Peripheral B-Cell Lymphoma

Lack of Surface Immunoglobulin Light Chain Expression by Flow Cytometric Immunophenotyping Can Help Diagnose Peripheral B-Cell Lymphoma Hematopathology / SURFACE IMMUNOGLOBULIN LIGHT CHAIN NEGATIVE PERIPHERAL B-CELL LYMPHOMA Lack of Surface Immunoglobulin Light Chain Expression by Flow Cytometric Immunophenotyping Can Help Diagnose Peripheral

More information

Mixed Phenotype Acute Leukemias

Mixed Phenotype Acute Leukemias Mixed Phenotype Acute Leukemias CHEN GAO; AMY M. SANDS; JIANLAN SUN NORTH AMERICAN JOURNAL OF MEDICINE AND SCIENCE APR 2012 VOL 5 NO.2 INTRODUCTION Most cases of acute leukemia can be classified based

More information

Multiparameter flow cytometry can be used to

Multiparameter flow cytometry can be used to Minimal residual disease testing in Acute Leukemia Anjum Hassan MD Assistant Professor of Pathology and Immunology, Director FISH laboratory in Anatomic Pathology, Washington University in St Louis, School

More information

CCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma

CCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma AJCP /CASE REPORT CCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma Yuan Miao, MD, 1,2 Pei Lin, MD, 1 Wei Wang, MD, 1 L. Jeffrey Medeiros, MD,

More information

Role of FISH in Hematological Cancers

Role of FISH in Hematological Cancers Role of FISH in Hematological Cancers Thomas S.K. Wan PhD,FRCPath,FFSc(RCPA) Honorary Professor, Department of Pathology & Clinical Biochemistry, Queen Mary Hospital, University of Hong Kong. e-mail: wantsk@hku.hk

More information

HEMATOPATHOLOGY SUMMARY REPORT RL;MMR;

HEMATOPATHOLOGY SUMMARY REPORT RL;MMR; HEMATOPATHOLOGY SUMMARY REPORT RL;MMR; Page 1 of 1 05/15/20XX HP000000-20XX 05/21/20XX (212) 123-457 (51) 32-3455 (51) 123-457 Age: 78 DOB: 0/05/19XX SS#: 45-45-45 Clinical Information: 78 y/o female with

More information

Abstract. Hematopathology / HEMATOGONE POPULATIONS

Abstract. Hematopathology / HEMATOGONE POPULATIONS Hematopathology / HEMATOGONE POPULATIONS Benign Hematogone-Rich Lymphoid Proliferations Can Be Distinguished From B-Lineage Acute Lymphoblastic Leukemia by Integration of Morphology, Immunophenotype, Adhesion

More information

V. Acute leukemia. Flow cytometry in evaluation of hematopoietic neoplasms: A case-based approach

V. Acute leukemia. Flow cytometry in evaluation of hematopoietic neoplasms: A case-based approach V. Acute leukemia Evaluating a sample for an acute leukemia Acute leukemia is a neoplasm of immature myeloid or lymphoid cells characterized by a block in maturation, usually at the stage of an early progenitor

More information

ADx Bone Marrow Report. Patient Information Referring Physician Specimen Information

ADx Bone Marrow Report. Patient Information Referring Physician Specimen Information ADx Bone Marrow Report Patient Information Referring Physician Specimen Information Patient Name: Specimen: Bone Marrow Site: Left iliac Physician: Accession #: ID#: Reported: 08/19/2014 - CHRONIC MYELOGENOUS

More information

Lymphoid Neoplasms Associated With IgM Paraprotein A Study of 382 Patients

Lymphoid Neoplasms Associated With IgM Paraprotein A Study of 382 Patients Hematopathology / LYMPHOMAS WITH IGM PARAPROTEIN Lymphoid Neoplasms Associated With IgM Paraprotein A Study of 382 Patients Pei Lin, MD, 1 Suyang Hao, MD, 1* Beverly C. Handy, MD, 2 Carlos E. Bueso-Ramos,

More information

CME/SAM. Mixed Phenotype Acute Leukemia

CME/SAM. Mixed Phenotype Acute Leukemia AJCP / Original Article Mixed Phenotype Acute Leukemia A Study of 61 Cases Using World Health Organization and European Group for the Immunological Classification of Leukaemias Criteria Olga K. Weinberg,

More information

WBCs Disorders 1. Dr. Nabila Hamdi MD, PhD

WBCs Disorders 1. Dr. Nabila Hamdi MD, PhD WBCs Disorders 1 Dr. Nabila Hamdi MD, PhD ILOs Compare and contrast ALL, AML, CLL, CML in terms of age distribution, cytogenetics, morphology, immunophenotyping, laboratory diagnosis clinical features

More information

Flow Cytometric Analysis of Acute Leukemias. Diagnostic Utility and Critical Analysis of Data

Flow Cytometric Analysis of Acute Leukemias. Diagnostic Utility and Critical Analysis of Data Flow Cytometric Analysis of Acute Leukemias Diagnostic Utility and Critical Analysis of Data Zahid Kaleem, MD; Eric Crawford, PhD; M. Hanif Pathan, MD; Leah Jasper, BS; Michael A. Covinsky, MD; Lawrence

More information

Gray Zones and Double Hits Distinguishing True Burkitt Lymphoma from Other High-Grade B-NHLs Burkitt Lymphoma Burkitt-Like Lymphoma DLBCL Patrick Tres

Gray Zones and Double Hits Distinguishing True Burkitt Lymphoma from Other High-Grade B-NHLs Burkitt Lymphoma Burkitt-Like Lymphoma DLBCL Patrick Tres Gray Zones and Double Hits Distinguishing True Burkitt Lymphoma from Other High-Grade B-NHLs Burkitt Lymphoma Burkitt-Like Lymphoma DLBCL Patrick Treseler, MD, PhD University of California San Francisco

More information

Aberrant Expression of CD7 in Myeloblasts Is Highly Associated With De Novo Acute Myeloid Leukemias With FLT3/ITD Mutation

Aberrant Expression of CD7 in Myeloblasts Is Highly Associated With De Novo Acute Myeloid Leukemias With FLT3/ITD Mutation Hematopathology / CD7 Expression and FLT3/ITD Mutation in AML Aberrant Expression of CD7 in Myeloblasts Is Highly Associated With De Novo Acute Myeloid Leukemias With FLT3/ITD Mutation Veronica Rausei-Mills,

More information

Hematology Measure #1: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow

Hematology Measure #1: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow Hematology Measure #1: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow This measure may be used as an Accountability measure Clinical Performance

More information

Immunopathology of Lymphoma

Immunopathology of Lymphoma Immunopathology of Lymphoma Noraidah Masir MBBCh, M.Med (Pathology), D.Phil. Department of Pathology Faculty of Medicine Universiti Kebangsaan Malaysia Lymphoma classification has been challenging to pathologists.

More information

Chronic Lymphocytic Leukemia FISH Panel. Impact on Diagnosis

Chronic Lymphocytic Leukemia FISH Panel. Impact on Diagnosis Hematopathology / CLL, FISH, AND 14Q32 TRANSLOCATIONS Chronic Lymphocytic Leukemia FISH Panel Impact on Diagnosis Beverly P. Nelson, MD, 1 Rohit Gupta, MD, 1 Gordon W. Dewald, PhD, 2 Sarah F. Paternoster,

More information

CME/SAM. Abstract. Hematopathology / CD103 and CD123 in B-Cell Neoplasia

CME/SAM. Abstract. Hematopathology / CD103 and CD123 in B-Cell Neoplasia Hematopathology / CD103 and CD123 in B-Cell Neoplasia Characteristic CD103 and CD123 Expression Pattern Defines Hairy Cell Leukemia Usefulness of CD123 and CD103 in the Diagnosis of Mature B-Cell Lymphoproliferative

More information

Phenotypic Heterogeneity of B Cells in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phenotypic Heterogeneity of B Cells in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Hematopathology / PHENOTYPIC HETEROGENEITY IN CLL/SLL Phenotypic Heterogeneity of B Cells in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Bal Kampalath, MD, 1 Maurice P. Barcos,

More information

Hematogones With Lambda Light Chain Restriction in a 4-Year-Old Boy With Burkitt Lymphoma: A Potential Diagnostic Pitfall

Hematogones With Lambda Light Chain Restriction in a 4-Year-Old Boy With Burkitt Lymphoma: A Potential Diagnostic Pitfall Hematogones With Lambda Light Chain Restriction in a 4-Year-Old Boy With Burkitt Lymphoma: A Potential Diagnostic Pitfall Tesha Guillory, MD, 1 Shiyong Li, MD, PhD, 1 Daniel J. Bergsagel, MD, 2 Elizabeth

More information

BCR-ABL1 positive Myeloid Sarcoma Nicola Austin

BCR-ABL1 positive Myeloid Sarcoma Nicola Austin BCR-ABL1 positive Myeloid Sarcoma Nicola Austin Cytocell UK & Ireland User Group Meeting Jesus College, Cambridge 4 th - 5 th April 2017 Myeloid Sarcoma WHO Classification Tumours of Haematopoietic and

More information

VUmc Basispresentatie

VUmc Basispresentatie Clinical diagnostic cytometry Gerrit J Schuurhuis Dept of Hematology VU University Medical Center Amsterdam, Netherlands Use of immunophenotyping at diagnosis to trace residual disease after therapy 1.

More information

The patient had a mild splenomegaly but no obvious lymph node enlargement. The consensus phenotype obtained from part one of the exercise was:

The patient had a mild splenomegaly but no obvious lymph node enlargement. The consensus phenotype obtained from part one of the exercise was: Case History An 86 year old male was admitted to hospital with chest infection. Haematological examination subsequently revealed the following: Hb- 11.0 g/dl; WBC- 67.1 x 10^9/l; PLT- 99 x10^9/l; RBC-

More information

Hematopathology Case Study

Hematopathology Case Study www.medfusionservices.com Hematopathology Case Study CV3515-14 JUNE Clinical Presentation: Clinical Information: A 42 year old male with history of chronic myelogenous leukemia (CML) presents with an elevated

More information

The Role of CD11c Expression in the Diagnosis of Mantle Cell Lymphoma

The Role of CD11c Expression in the Diagnosis of Mantle Cell Lymphoma Hematopathology / CD11c Expression in Mantle Cell Lymphoma The Role of CD11c Expression in the Diagnosis of Mantle Cell Lymphoma Teresa S. Kraus, MD, * Christine N. Sillings, MD, * Debra F. Saxe, PhD,

More information

Test Name Results Units Bio. Ref. Interval. Positive

Test Name Results Units Bio. Ref. Interval. Positive LL - LL-ROHINI (NATIONAL REFERENCE 135091533 Age 28 Years Gender Male 1/9/2017 120000AM 1/9/2017 105415AM 4/9/2017 23858M Ref By Final LEUKEMIA DIAGNOSTIC COMREHENSIVE ROFILE, ANY 6 MARKERS t (1;19) (q23

More information

Test Name Results Units Bio. Ref. Interval. Positive

Test Name Results Units Bio. Ref. Interval. Positive Lab No 135091548 Age 35 Years Gender Female 1/9/2017 120000AM 1/9/2017 103420AM 4/9/2017 23753M Ref By Dr UNKNWON Final Test Results Units Bio Ref Interval LEUKEMIA DIAGNOSTIC COMREHENSIVE ROFILE 3 t (1;19)

More information

NUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia

NUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia Case 0094 NUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia Jessica Snider, MD Medical University of South Carolina Case Report - 64 year old Caucasian Male Past Medical History Osteoarthritis

More information

FLOCK Cluster Analysis of Mast Cell Event Clustering by High-Sensitivity Flow Cytometry Predicts Systemic Mastocytosis

FLOCK Cluster Analysis of Mast Cell Event Clustering by High-Sensitivity Flow Cytometry Predicts Systemic Mastocytosis FLOCK Cluster Analysis of Mast Cell Event Clustering by High-Sensitivity Flow Cytometry Predicts Systemic Mastocytosis David M. Dorfman, MD, PhD, Charlotte D. LaPlante, Olga Pozdnyakova, MD, PhD, and Betty

More information

FLOW CYTOMETRY PRINCIPLES AND PRACTICE. Toby Eyre Consultant Haematologist Oxford University Hospitals NHS Foundation Trust June 2018

FLOW CYTOMETRY PRINCIPLES AND PRACTICE. Toby Eyre Consultant Haematologist Oxford University Hospitals NHS Foundation Trust June 2018 FLOW CYTOMETRY PRINCIPLES AND PRACTICE Toby Eyre Consultant Haematologist Oxford University Hospitals NHS Foundation Trust June 2018 Aims and Objectives Principles of flow cytometry Preparation Steps involved

More information

Acute Lymphoblastic Leukemia in Elderly Patients The Philadelphia Chromosome May Not Be a Significant Adverse Prognostic Factor

Acute Lymphoblastic Leukemia in Elderly Patients The Philadelphia Chromosome May Not Be a Significant Adverse Prognostic Factor Hematopathology / ACUTE LYMPHOBLASTIC LEUKEMIA IN ELDERLY PATIENTS Acute Lymphoblastic Leukemia in Elderly Patients The Philadelphia Chromosome May Not Be a Significant Adverse Prognostic Factor Mihaela

More information

Case Report Parotid gland follicular lymphoma lacking both cytoplasmic and surface light chains: a rare case

Case Report Parotid gland follicular lymphoma lacking both cytoplasmic and surface light chains: a rare case Int J Clin Exp Pathol 2014;7(10):7100-7104 www.ijcep.com /ISSN:1936-2625/IJCEP0001717 Case Report Parotid gland follicular lymphoma lacking both cytoplasmic and surface light chains: a rare case Jenny

More information

Clinical question. Screening tube. Diagnostic panel MRD. Clinical question

Clinical question. Screening tube. Diagnostic panel MRD. Clinical question OW CYTOMETRY UPDATES IN LYMPHOPROLIFERATIVE DISORDERS CANCER RESEARCH CENTER IBSAL UNIVERSITY & UNIVERSITY HOSPITAL, SALAMANCA (SPAIN) DISCLOSURES The EuroFlow Scientific Consortium Iamco-chairof receives

More information

Myelodysplastic Syndrome Case 158

Myelodysplastic Syndrome Case 158 Myelodysplastic Syndrome Case 158 Dong Chen MD PhD Division of Hematopathology Mayo Clinic Clinical History 86 year old man Persistent borderline anemia and thrombocytopenia. His past medical history was

More information

Diagnostic Usefulness of CD23 and FMC-7 Antigen Expression Patterns in B-Cell Lymphoma Classification

Diagnostic Usefulness of CD23 and FMC-7 Antigen Expression Patterns in B-Cell Lymphoma Classification Hematopathology / AND ANTIGEN EXPRESSION IN B-CELL LYMPHOMA CLASSIFICATION Diagnostic Usefulness of and Antigen Expression Patterns in B-Cell Lymphoma Classification Diana P. Garcia, MD, 1* Michele T.

More information

Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure

Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure I am receiving an honorarium from Sysmex for today s presentation. 1 Determining the Etiology for

More information

Multidimensional Flow Cytometry for Detection of Rare Populations in Hematological Malignancies

Multidimensional Flow Cytometry for Detection of Rare Populations in Hematological Malignancies TZU CHI MED J March 2009 Vol 21 No 1 available at http://ajws.elsevier.com/tcmj Tzu Chi Medical Journal Original Article Multidimensional Flow Cytometry for Detection of Rare Populations in Hematological

More information

Extramedullary precursor T-lymphoblastic transformation of CML at presentation

Extramedullary precursor T-lymphoblastic transformation of CML at presentation Extramedullary precursor T-lymphoblastic transformation of CML at presentation Neerja Vajpayee, Constance Stein, Bernard Poeisz & Robert E. Hutchison Clinical History 30 year old man presented to the emergency

More information

Acute myeloid leukemia. M. Kaźmierczak 2016

Acute myeloid leukemia. M. Kaźmierczak 2016 Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production

More information

7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour

7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour 7 Omar Abu Reesh Dr. Ahmad Mansour Dr. Ahmad Mansour -Leukemia: neoplastic leukocytes circulating in the peripheral bloodstream. -Lymphoma: a neoplastic process in the lymph nodes, spleen or other lymphatic

More information

Do Your Flow Cytometric LDTs. Validation Guidelines? Fiona E. Craig, MD University of Pittsburgh School of Medicine

Do Your Flow Cytometric LDTs. Validation Guidelines? Fiona E. Craig, MD University of Pittsburgh School of Medicine Do Your Flow Cytometric LDTs Conform to the ICSH ICCS Validation Guidelines? Fiona E. Craig, MD University of Pittsburgh School of Medicine How should LDTs be validated? Accuracy Specificity Sensitivity

More information

Welcome. Welcome. Emerging Technologies in Flow Cytometry

Welcome. Welcome. Emerging Technologies in Flow Cytometry Emerging Technologies in Flow Cytometry Dr. William Dittman December 11, 2012 You may download a copy of the handout by clicking on the handout icon, located in the upper right hand corner of your screen

More information

Mast Cell Disease Case 054 Session 7

Mast Cell Disease Case 054 Session 7 Mast Cell Disease Case 054 Session 7 Rodney R. Miles, M.D., Ph.D. Lauren B. Smith, M.D. Cem Akin, M.D. Diane Roulston,, Ph.D. Charles W. Ross, M.D. Departments of Pathology and Internal Medicine University

More information

Therapy-related MDS/AML with KMT2A (MLL) Rearrangement Following Therapy for APL Case 0328

Therapy-related MDS/AML with KMT2A (MLL) Rearrangement Following Therapy for APL Case 0328 Therapy-related MDS/AML with KMT2A (MLL) Rearrangement Following Therapy for APL Case 0328 Kenneth N. Holder, Leslie J. Greebon, Gopalrao Velagaleti, Hongxin Fan, Russell A. Higgins Initial Case: Clinical

More information

Case Report A case of EBV positive diffuse large B-cell lymphoma of the adolescent

Case Report A case of EBV positive diffuse large B-cell lymphoma of the adolescent Int J Clin Exp Med 2014;7(1):307-311 www.ijcem.com /ISSN:1940-5901/IJCEM1311029 Case Report A case of EBV positive diffuse large B-cell lymphoma of the adolescent Qilin Ao 2, Ying Wang 1, Sanpeng Xu 2,

More information

Anaplastic Large Cell Lymphoma A Flow Cytometric Analysis of 29 Cases

Anaplastic Large Cell Lymphoma A Flow Cytometric Analysis of 29 Cases Hematopathology / FLOW CYTOMETRY OF ANAPLASTIC LYMPHOMA Anaplastic Large Cell Lymphoma A Flow Cytometric Analysis of 29 Cases Melissa V. Kesler, MD, Geeta S. Paranjape, MD, Sheryl L. Asplund, MD, Robert

More information

Original Article Acute Leukemias And Aberrant Markers Expression Pak Armed Forces Med J 2018; 68 (3):

Original Article Acute Leukemias And Aberrant Markers Expression Pak Armed Forces Med J 2018; 68 (3): Open Access Original Article Acute Leukemias And Aberrant Markers Expression Pak Armed Forces Med J 2018; 68 (3): 450-54 SPECTRUM OF ACUTE LEUKEMIAS AND ABERRANT MARKERS EXPRESSION BASED ON FLOWCYTOMETRY

More information

Case 1. Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX

Case 1. Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX Case 1 Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX Disclosure of Relevant Financial Relationships The USCAP requires that anyone in a position to influence or control the content of all CME

More information

Mantle Cell Lymphoma

Mantle Cell Lymphoma HEMATOPATHOLOGY Original Article Mantle Cell Lymphoma Morphologic Findings in Bone Marrow Involvement JAY WASMAN, MD, 1 NANCY S. ROSENTHAL, MD,' AND DIANE C. FARHI, MD 2 Although mantle cell lymphoma (MCL),

More information

Flow cytometric analysis of B-cell lymphoproliferative disorders

Flow cytometric analysis of B-cell lymphoproliferative disorders Flow cytometric analysis of B-cell lymphoproliferative disorders David M. Dorfman, M.D., Ph.D. Department of Pathology Brigham and Women s Hospital and Harvard Medical School Boston, MA Objectives Review

More information

Fluorescent In-Situ Hybridization is the Hand Mirror of Cytogenetics: A Rare Case of Near Tetraploidy in Pediatric Acute Lymphoblastic Leukemia

Fluorescent In-Situ Hybridization is the Hand Mirror of Cytogenetics: A Rare Case of Near Tetraploidy in Pediatric Acute Lymphoblastic Leukemia American Journal of Cancer Case Reports Rajan A et al. American Journal of Cancer Case Reports 2016, 4:156-160 http://ivyunion.org/index.php/ajccr/ Page 1 of 5 Case Report Fluorescent In-Situ Hybridization

More information

CLASSIFICATION OF NINETY-EIGHT ADULT CASES OF ACUTE LEUKEMIAS ACCORDING TO MORPHOLOGY, IMMUNOLOGY AND CYTOGENETICS

CLASSIFICATION OF NINETY-EIGHT ADULT CASES OF ACUTE LEUKEMIAS ACCORDING TO MORPHOLOGY, IMMUNOLOGY AND CYTOGENETICS ( ;hinese Journal qf()ancer Research 8(3): 209 ~ 13, 1996. CLASSIFICATION OF NINETY-EIGHT ADULT CASES OF ACUTE LEUKEMIAS ACCORDING TO MORPHOLOGY, IMMUNOLOGY AND CYTOGENETICS Li Jianyong ~2tt[. N Xue Yongquan

More information

Canadian College of Medical Geneticists (CCMG) Cytogenetics Examination. May 4, 2010

Canadian College of Medical Geneticists (CCMG) Cytogenetics Examination. May 4, 2010 Canadian College of Medical Geneticists (CCMG) Cytogenetics Examination May 4, 2010 Examination Length = 3 hours Total Marks = 100 (7 questions) Total Pages = 8 (including cover sheet and 2 pages of prints)

More information

Case Report Blasts-more than meets the eye: evaluation of post-induction day 21 bone marrow in CBFB rearranged acute leukemia

Case Report Blasts-more than meets the eye: evaluation of post-induction day 21 bone marrow in CBFB rearranged acute leukemia Int J Clin Exp Pathol 2014;7(7):4498-4502 www.ijcep.com /ISSN:1936-2625/IJCEP0000851 Case Report Blasts-more than meets the eye: evaluation of post-induction day 21 bone marrow in CBFB rearranged acute

More information

Acute Lymphoblastic and Myeloid Leukemia

Acute Lymphoblastic and Myeloid Leukemia Acute Lymphoblastic and Myeloid Leukemia Pre- and Post-Disease Form Acute Lympoblastic Leukemia Mary Eapen MD, MS Acute Lymphoblastic Leukemia SEER Age-adjusted incidence rate 1.6 per 100,000 men and women

More information

PRECURSOR LYMHPOID NEOPLASMS. B lymphoblastic leukaemia/lymphoma T lymphoblastic leukaemia/lymphoma

PRECURSOR LYMHPOID NEOPLASMS. B lymphoblastic leukaemia/lymphoma T lymphoblastic leukaemia/lymphoma PRECURSOR LYMHPOID NEOPLASMS B lymphoblastic leukaemia/lymphoma T lymphoblastic leukaemia/lymphoma B lymphoblastic leukaemia/lymphoma Definition: B lymphoblastic leukaemia/lymphoma is a neoplasm of precursor

More information

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017 LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer

More information

FLOW CYTOMETRIC ANALYSIS OF NORMAL BONE MARROW

FLOW CYTOMETRIC ANALYSIS OF NORMAL BONE MARROW XI International Conference Hematopoiesis Immunology Budapest, June 6-7, 2014 FLO CYTOMETRIC ANALYSIS OF NORMAL BONE MARRO Bruno Brando and Arianna Gatti Hematology Laboratory and Transfusion Center Legnano

More information

NUMERATOR: Patients who had baseline cytogenetic testing performed on bone marrow

NUMERATOR: Patients who had baseline cytogenetic testing performed on bone marrow Quality ID #67 (NQF 0377): Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow National Quality Strategy Domain: Effective Clinical Care

More information

Flow Cytometric Analysis of CD5+ B Cells A Frame of Reference for Minimal Residual Disease Analysis in Chronic Lymphocytic Leukemia

Flow Cytometric Analysis of CD5+ B Cells A Frame of Reference for Minimal Residual Disease Analysis in Chronic Lymphocytic Leukemia Hematopathology / CD5+ -CELL NLYSIS Y FLOW CYTOMETRY Flow Cytometric nalysis of CD5+ Cells Frame of Reference for Minimal Residual Disease nalysis in Chronic Lymphocytic Leukemia Ritu Gupta, MD, 1 Paresh

More information

B-Lymphoblastic Leukemia in Patients With Chronic Lymphocytic Leukemia. A Report of Four Cases

B-Lymphoblastic Leukemia in Patients With Chronic Lymphocytic Leukemia. A Report of Four Cases AJCP / Case Report B-Lymphoblastic Leukemia in Patients With Chronic Lymphocytic Leukemia A Report of Four Cases Zaher Chakhachiro, MD, C. Cameron Yin, MD, PhD, Lynne V. Abruzzo, MD, PhD, Tariq N. Aladily,

More information

Case #16: Diagnosis. T-Lymphoblastic lymphoma. But wait, there s more... A few weeks later the cytogenetics came back...

Case #16: Diagnosis. T-Lymphoblastic lymphoma. But wait, there s more... A few weeks later the cytogenetics came back... Case #16: Diagnosis T-Lymphoblastic lymphoma But wait, there s more... A few weeks later the cytogenetics came back... 46,XY t(8;13)(p12;q12)[12] Image courtesy of Dr. Xinyan Lu Further Studies RT-PCR

More information

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma

More information

Fluorescence in-situ Hybridization (FISH) ETO(RUNX1T1)/AML1(RUNX1) or t(8;21)(q21.3;q22)

Fluorescence in-situ Hybridization (FISH) ETO(RUNX1T1)/AML1(RUNX1) or t(8;21)(q21.3;q22) PML/RARA t(15;17) Translocation Assay Result : nuc ish(pml 2)(RARA 2)[200] : 200/200(100%) interphase nuclei show normal 2O 2G signals for PML/RARA : is Negative for t(15;17)(q22;q21.1) 2 Orange 2 Green

More information

Mimics of Lymphoma in Routine Biopsies. Mixed follicular and paracortical hyperplasia. Types of Lymphoid Hyperplasia

Mimics of Lymphoma in Routine Biopsies. Mixed follicular and paracortical hyperplasia. Types of Lymphoid Hyperplasia Mimics of Lymphoma in Routine Biopsies Patrick Treseler, MD, PhD Professor of Pathology University of California San Francisco Types of Lymphoid Hyperplasia Follicular hyperplasia (B-cells) Paracortical

More information

2013 AAIM Pathology Workshop

2013 AAIM Pathology Workshop 2013 AAIM Pathology Workshop John Schmieg, M.D., Ph.D. None Disclosures 1 Pathology Workshop Objectives Define the general philosophy of reviewing pathology reports Review the various components of Bone

More information

Dr Prashant Tembhare

Dr Prashant Tembhare Dr Prashant Tembhare docprt@gmail.com FCM very powerful technology in Identification and characterization of neoplastic plasma cells as it allows - simultaneous assessment of multiple antigens large numbers

More information

Comparison of myeloperoxidase detection by flow cytometry using two different clones of monoclonal antibodies

Comparison of myeloperoxidase detection by flow cytometry using two different clones of monoclonal antibodies Malaysian J Pathol 2004; 26(2) : 111 116FLOW CYTOMETRY MYELOPEROXIDASE DETECTION Comparison of myeloperoxidase detection by flow cytometry using two different clones of monoclonal antibodies CF Leong MPath,

More information

Leukemic Phase of Mantle Cell Lymphoma, Blastoid Variant

Leukemic Phase of Mantle Cell Lymphoma, Blastoid Variant Hematopathology / LEUKEMIC BLASTOID MANTLE CELL LYMPHOMA Leukemic Phase of Mantle Cell Lymphoma, Blastoid Variant Timothy P. Singleton, MD, Margaret M. Anderson, MD, Charles W. Ross, MD, and Bertram Schnitzer,

More information

Acute lymphoblastic leukemia (ALL) represents approximately

Acute lymphoblastic leukemia (ALL) represents approximately Terminal Deoxynucleotidyl Transferase Negative Acute Lymphoblastic Leukemia Joana Faber, MD; Hagop Kantarjian, MD; W. Mark oberts, MD; Michael Keating, MD; Emil Freireich, MD; Maher Albitar, MD Objective.

More information

Cleveland Clinic Laboratories Hematology Diagnostic Services. Trust in us for everything you need in a reference lab.

Cleveland Clinic Laboratories Hematology Diagnostic Services. Trust in us for everything you need in a reference lab. Cleveland Clinic Laboratories Hematology Diagnostic Services Trust in us for everything you need in a reference lab. Our Mission The Pathology and Laboratory Medicine Institute contributes to excellent

More information

Bone Marrow Evaluation of cases of Leukemia in Pathology Department, BJGMC, Pune

Bone Marrow Evaluation of cases of Leukemia in Pathology Department, BJGMC, Pune Original article: Bone Marrow Evaluation of cases of Leukemia in Pathology Department, BJGMC, Pune Shingade MS, Shah RN, Sontakke AR, Puranik SC Name of Institute / College: B. J. Govt. Medical College

More information

Critical Analysis and Diagnostic Usefulness of Limited Immunophenotyping of B-Cell Non-Hodgkin Lymphomas by Flow Cytometry

Critical Analysis and Diagnostic Usefulness of Limited Immunophenotyping of B-Cell Non-Hodgkin Lymphomas by Flow Cytometry Hematopathology / FLOW CYTOMETRIC IMMUNOPHENOTYPING IN B-CELL NON-HODGKIN LYMPHOMA Critical Analysis and Diagnostic Usefulness of Limited Immunophenotyping of B-Cell Non-Hodgkin Lymphomas by Flow Cytometry

More information

Mimics of Lymphoma in Routine Biopsies. I have nothing to disclose regarding the information to be reported in this talk.

Mimics of Lymphoma in Routine Biopsies. I have nothing to disclose regarding the information to be reported in this talk. Mimics of Lymphoma in Routine Biopsies Patrick Treseler, MD, PhD Professor of Pathology University of California San Francisco I have nothing to disclose regarding the information to be reported in this

More information

Test Utilization: Chronic Lymphocytic Leukemia

Test Utilization: Chronic Lymphocytic Leukemia Test Utilization: Chronic Lymphocytic Leukemia Initial Evaluation Diagnostic Criteria Selection of Tests for Prognosis Response to Therapy Challenges Assessment for persistent disease Paul J. Kurtin, M.D.

More information

JMSCR Vol. 03 Issue 06 Page June 2015

JMSCR Vol. 03 Issue 06 Page June 2015 www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x An Indolent Natural Killer Cell Leukemia Presenting with Bilateral Ankle Arthritis and Low Grade Fever Abstract Author Subhash Chandra

More information

Standard immunophenotyping of leukemia cells in acute myeloid leukemia (AML)

Standard immunophenotyping of leukemia cells in acute myeloid leukemia (AML) Clinical immunology Standard immunophenotyping of leukemia cells in acute myeloid leukemia (AML) ` JOLANTA WOZNIAK, JOANNA KOPEÆ-SZLÊZAK Department of Haematological Cytobiology, Institut of Haematology

More information

Initial Diagnostic Workup of Acute Leukemia

Initial Diagnostic Workup of Acute Leukemia Initial Diagnostic Workup of Acute Leukemia Guideline from the College of American Pathologists (CAP) and the American Society of Hematology (ASH) Publication: Archives of Pathology and Laboratory Medicine

More information

Aggressive B-cell Lymphomas Updated WHO classification Elias Campo

Aggressive B-cell Lymphomas Updated WHO classification Elias Campo Aggressive B-cell Lymphomas Updated WHO classification Elias Campo Hospital Clinic, University of Barcelona Diffuse Large B-cell Lymphoma A Heterogeneous Category Subtypes with differing: Histology and

More information

BLOOD RESEARCH ORIGINAL ARTICLE INTRODUCTION. Department of Hematology, All India Institute of Medical Sciences, New Delhi, India

BLOOD RESEARCH ORIGINAL ARTICLE INTRODUCTION. Department of Hematology, All India Institute of Medical Sciences, New Delhi, India BLOOD RESEARCH VOLUME 49 ㆍ NUMBER 4 December 2014 ORIGINAL ARTICLE Aberrant myeloid antigen co-expression is correlated with high percentages of CD34-positive cells among blasts of acute lymphoblastic

More information

Cost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic

Cost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic Cost-Effective Strategies in the Workup of Hematologic Neoplasm Karl S. Theil, Claudiu V. Cotta Cleveland Clinic In the past 12 months, we have not had a significant financial interest or other relationship

More information

Collected: , PM Sent: , PM Received: , PM Preliminary: , PM. Notification Status: COMPREHENSIVE DIAGNOSIS

Collected: , PM Sent: , PM Received: , PM Preliminary: , PM. Notification Status: COMPREHENSIVE DIAGNOSIS PATIENT Name:HIPAA, Compliant DOB: 03-25-1945 (60 yr) ID#: xxx-xx-0000 Sex: M Tel: xxx-xxx-xxxx SPECIMEN Your No:WS05-xxxx Case No:C05-00xxx Req. No:Txxxxx Collected: 06-08-05, PM Sent: 06-09-05, PM Received:

More information

Case Report Follicular lymphoma mimicking marginal zone lymphoma in lymph node: a case report

Case Report Follicular lymphoma mimicking marginal zone lymphoma in lymph node: a case report Int J Clin Exp Pathol 2014;7(10):7076-7081 www.ijcep.com /ISSN:1936-2625/IJCEP0001940 Case Report Follicular lymphoma mimicking marginal zone lymphoma in lymph node: a case report Ikuo Matsuda 1, Yoshifumi

More information

Lymphoblastic Leukemia / Lymphoma

Lymphoblastic Leukemia / Lymphoma 1 5014 - Topics in Pediatric Hematopathology: Acute Lymphoblastic Leukemia, Including Changes in the Revised WHO Classification, and Unusual Pediatric Myeloid Neoplasms Robert W. McKenna, MD MASCP * Elizabeth

More information